IP Library › Granted Patent US 8,785,606
Granted Patent B2
US 8,785,606 · App. 13/451,968 · Granted Jul 22, 2014

Compositions and methods for promoting neuronal outgrowth

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,785,606
App. No.
13/451,968
Granted
Jul 22, 2014
Kind
B2
Abstract

Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.

Claims (21)

1. A method of treating a mammal having a spinal cord injury comprising administering an effective amount of chondroitinase AC, chondroitinase B, or a mixture thereof to the mammal.

2. The method of claim 1 , wherein administering is selected from topical, local and systemic.

3. The method of claim 1 , wherein chondroitinase AC is administered.

4. The method of claim 3 , wherein the chondroitinase AC is selected from the group consisting of chondroitinase AC, chondroitinase AC II and chondroitinase AC III.

5. The method of claim 1 , wherein chondroitinase B is administered.

6. The method of claim 1 , wherein a combination of a chondroitinase AC and chondroitinase B is administered.

7. The method of claim 1 , wherein the chondroitinase AC, chondroitinase B or a mixture thereof is administered as a composition comprising a pharmaceutically acceptable carrier.

8. The method of claim 2 , wherein local administration uses a mode selected from a catheter, a syringe, and direct application to the injury.

9. The method of claim 1 , wherein the effective amount is administered in multiple doses.

10. The method of claim 1 , wherein the mammal is a human.

11. A method of promoting neurite outgrowth in a mammal having a spinal cord injury comprising administering an effective amount of chondroitinase AC, chondroitinase B, or a mixture thereof to the subject.

12. The method of claim 11 , wherein the neurite outgrowth is in the central nervous system.

13. The method of claim 11 , wherein administering is selected from topical, local and systemic.

14. The method of claim 11 , wherein chondroitinase AC is administered.

15. The method of claim 14 , wherein the chondroitinase AC is selected from the group consisting of chondroitinase AC, chondroitinase AC II and chondroitinase AC III.

16. The method of claim 11 , wherein chondroitinase B is administered.

17. The method of claim 11 , wherein a combination of a chondroitinase AC and chondroitinase B is administered.

18. The method of claim 11 , wherein the chondroitinase AC, chondroitinase B or a mixture thereof is administered as a composition comprising a pharmaceutically acceptable carrier.

19. The method of claim 13 , wherein local administration uses a mode selected from a catheter, a syringe, and direct application to the injury.

20. The method of claim 11 , wherein the effective amount is administered in multiple doses.

21. The method of claim 11 , wherein the mammal is a human.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 20, 2012
From: GRUSKIN, ELLIOTT A.; IACI, JENNIFER F.; VECCHIONE, ANDREA M.; KASPERBAUER, SARAH J.; ROY, GARGI
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 028082/0100 →